Seqirus Inc.
Holly Springs, NC
- UEI
- Z6N1LJ2RD6E3
- CAGE
- 7L0Y8
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 475 Green Oaks Pkwy, Holly Springs, NC 27540, USA
- Website
- cslseqirus.us
- Founded
- 1916
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $121,649,709 |
| FY2025 | $86,157,162 |
| FY2024 | $337,168,791 |
| FY2023 | $85,204,862 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $121,649,709 |
Contract vehicles
No active vehicles.
1 expired vehicle
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Glaxosmithkline, LLC | Durham, NC | 325412 Pharmaceutical Preparation Manufacturing |
| Sanofi Pasteur Inc. | Swiftwater, PA | 325414 Biological Product (except Diagnostic) Manufacturing |
| Astrazeneca Pharmaceuticals LP | Wilmington, DE | 325412 Pharmaceutical Preparation Manufacturing |
| Albert B. Sabin Vaccine Institute, Inc. (The) | Washington, DC | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Reithera S.R.L. | Castel Romano, Lazio | 325414 Biological Product (except Diagnostic) Manufacturing |
About the company
Seqirus Inc., a foreign-owned manufacturer of biological products based in Holly Springs, North Carolina, develops and manufactures pandemic preparedness vaccines and medical countermeasures for the federal government as a prime contractor under a single-award Indefinite Delivery Contract with the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response. The vendor operates exclusively in the full-and-open competitive space with no set-aside designations across its federal footprint.
Seqirus's customer concentration is absolute — all 47 awards across the past five years derive from HHS ASPR, which accounts for the full $34.94 billion in combined potential value. The vendor holds a primary $13.4 billion single-award IDC (contract 75A50122D00004) awarded February 22, 2022, with an ultimate completion date of February 21, 2027. Under that parent vehicle, HHS ASPR has issued 15 task orders carrying $509.9 million in combined potential value. Seqirus also operates under two legacy pandemic preparedness contracts: Indefinite Delivery Contract 75A50118D00004 (9 task orders, $28.4 million) and the Pandemic Influenza Preparedness and Response 2012-2016 vehicle (11 task orders, $55.9 million).
The vendor's capability portfolio centers on cGMP manufacturing of influenza vaccines, including master and working seed lot development, bulk antigen acquisition, formulation and filling of vaccine doses, clinical trial support, and stability testing and storage of vaccine stockpiles. Representative work includes a $349.3 million delivery order issued May 3, 2024, for H5 pandemic readiness medical countermeasures acquisition; a $42.8 million order issued September 30, 2026, for formulation and filling of MF59-adjuvanted cell-based A/Henan/4-10CNIC/2022 (H3N8)-like vaccine and clinical trial implementation with completion to March 29, 2030; and a $30.7 million order issued September 19, 2022, for Influenza A/Astrakhan/3212/2020 (H5N8)-like master and working seed lots plus vaccine candidate and clinical trial support. Additional recent orders include a $28.7 million task for manufacture and stability studies of thimerosal-free pandemic influenza vaccine multidose vials (September 30, 2026, completing September 29, 2029) and a $23.3 million order for storage and stability testing of vaccine bulk lots (February 22, 2024, completing May 21, 2027). All work is performed at the Holly Springs, North Carolina facility. The vendor's work is classified under NAICS 325414 (Biological Product Manufacturing) for 40 of 47 awards, with the remainder under biotechnology R&D classifications.
Award activity has been cyclical — one award in 2021, five in 2022, three in 2023, four in 2024, and four in 2026 — reflecting the episodic nature of pandemic preparedness procurement. Four awards with combined potential value of $45.5 million reach ultimate completion inside the next twenty-four months, exposing $45.5 million in recompete opportunity. The vendor obligated $1.91 billion against the $34.94 billion combined potential value across all awards, representing a 5% obligation rate consistent with long-term stockpile and preparedness contracting.
Quick answers
Is Seqirus Inc. registered in SAM.gov?
Yes. Seqirus Inc.'s SAM.gov registration is active through November 13, 2026.
Which contract vehicles does Seqirus Inc. hold?
Seqirus Inc. holds a place on 1 federal contract vehicle: Pandemic Influenza Preparedness and Response 2012-2016.
How much has Seqirus Inc. received in federal contracts?
Federal contracts obligated $86,157,162 to Seqirus Inc. in fiscal year 2025 and $630,180,523 in fiscal years 2023 through 2027.
How does Seqirus Inc. rank among federal contractors?
Seqirus Inc. ranked #4 in PSC AD, #5 in NAICS 23621 and #5 in NAICS 325414 in FY2025.
What is Seqirus Inc.'s most recent federal award?
Seqirus Inc.'s most recent federal contract award is Formulation and filling of MF59-adjuvanted cell-based a/henan/4-10CNIC/2022 (H3N8)-like vaccine and clinical trial… (75A50126F61015), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2026.
On GovTribe
See Seqirus Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors